Plozasiran Clinical Trials (2026): 8 Studies for Severe Hypertriglyceridemia & Familial Chylomicronemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
8 Plozasiran clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Severe Hypertriglyceridemia & Familial Chylomicronemia) and 3,482 total planned enrollment. 7 Phase 3 Plozasiran trials are listed. 2 Plozasiran clinical trials are actively recruiting at 24 U.S. sites across 17 states. Most recent activity: NCT06880770 (Jun 2029).
Where to Participate: All Plozasiran Trial Sites in the U.S. (24 sites across 17 states)
Every actively recruiting Plozasirantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Research Site | Los Angeles90027 | NCT06880770 | Map |
| CA | Research Site 275 | Redding96001 | NCT06822790 | Map |
| CA | Clinical Research Site 4 | Santa Clarita91321 | NCT06880770 | Map |
| CT | Research Site | New Haven06519 | NCT06880770 | Map |
| GA | Research Site 237 | Lawrenceville30044 | NCT06822790 | Map |
| IL | Clinical Research Site 6 | Springfield62702 | NCT06880770 | Map |
| IN | Research Site | Indianapolis46202 | NCT06880770 | Map |
| KS | Research Site | Kansas City66160 | NCT06880770 | Map |
| MI | Research Site | Ann Arbor48109 | NCT06880770 | Map |
| MN | Research Site 290 | Minneapolis55455 | NCT06822790 | Map |
| MO | Research Site | St Louis63110 | NCT06880770 | Map |
| NE | Clinical Research Site 5 | North Platte69101 | NCT06880770 | Map |
| NY | Research Site 72 | Long Island City11106 | NCT06822790 | Map |
| NC | Clinical Research Site 3 | Greensboro27401 | NCT06880770 | Map |
| NC | Research Site | Wilmington28412 | NCT06880770 | Map |
| NC | Research Site 169 | Wilmington28401 | NCT06822790 | Map |
| OH | Research Site 234 | Columbus43214 | NCT06822790 | Map |
| OH | Research Site 294 | Vandalia45377 | NCT06822790 | Map |
| PA | Clinical Research Site 7 | Philadelphia19107 | NCT06880770 | Map |
| PA | Research Site | Pittsburgh15213 | NCT06880770 | Map |
| TN | Research Site 293 | Chattanooga37411 | NCT06822790 | Map |
| TX | Clinical Research Site 1 | Mesquite75149 | NCT06880770 | Map |
| TX | Clinical Research Site 2 | San Antonio78233 | NCT06880770 | Map |
| WA | Research Site | Seattle98109 | NCT06880770 | Map |
Plozasiran clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | available | Total |
|---|---|---|---|---|---|
| P3 | 2 | 3 | 2 | 7 | |
| N/A | 1 | 1 |
Recruiting Plozasiran clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06880770 | SHASTA-5Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | P3 | Severe Hypertriglyceridemia | 288 | Apr 2025 |
| NCT06822790 | SHASTA-10Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | P3 | Hypertriglyceridemia | 869 | Apr 2025 |
Plozasiran clinical trials by indication
Severe Hypertriglyceridemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06880770 | SHASTA-5 | P3 | recruiting | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis |
| NCT06347016 | SHASTA-4 | P3 | active not recruiting | Study of Plozasiran in Adults With Severe Hypertriglyceridemia |
| NCT06347003 | SHASTA-3 | P3 | active not recruiting | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia |
Hypertriglyceridemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06822790 | SHASTA-10 | P3 | recruiting | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia |
| NCT06347133 | MUIR-3 | P3 | active not recruiting | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia |
Familial Chylomicronemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05089084 | PALISADE | P3 | completed | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) |
| NCT06796426 | SHTG | N/A | available | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS |
Familial Chylomicronemia Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05902598 | — | P3 | completed | A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome |
Plozasiran pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SHASTA-5 | NCT06880770 | P3 | recruiting | Severe Hypertriglyceridemia | 288 | — |
| SHASTA-10 | NCT06822790 | P3 | recruiting | Hypertriglyceridemia | 869 | — |
| SHASTA-4 | NCT06347016 | P3 | active not recruiting | Severe Hypertriglyceridemia | 311 | — |
| SHASTA-3 | NCT06347003 | P3 | active not recruiting | Severe Hypertriglyceridemia | 446 | — |
| MUIR-3 | NCT06347133 | P3 | active not recruiting | Hypertriglyceridemia | 1,456 | — |
| PALISADE | NCT05089084 | P3 | completed | Familial Chylomicronemia | 75 | — |
All Plozasiran trials (8)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06880770 | SHASTA-5 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | P3 | recruiting | 288 | Arrowhead Pharmaceuticals | Apr 2025 |
| NCT06822790 | SHASTA-10 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | P3 | recruiting | 869 | Arrowhead Pharmaceuticals | Apr 2025 |
| NCT06347016 | SHASTA-4 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | P3 | active not recruiting | 311 | Arrowhead Pharmaceuticals | Jul 2024 |
| NCT06347003 | SHASTA-3 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | P3 | active not recruiting | 446 | Arrowhead Pharmaceuticals | Jul 2024 |
| NCT06347133 | MUIR-3 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | P3 | active not recruiting | 1,456 | Arrowhead Pharmaceuticals | May 2024 |
| NCT05089084 | PALISADE | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | P3 | completed | 75 | Arrowhead Pharmaceuticals | Dec 2021 |
| NCT05902598 | A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome | P3 | completed | 37 | Visirna Therapeutics HK Limited | Jul 2023 | |
| NCT06796426 | SHTG | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS | — | available | 0 | Arrowhead Pharmaceuticals | — |
Plozasiran clinical trials: frequently asked questions
- How many Plozasiran clinical trials are there?
- 8 Plozasiran clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 2 are marked completed.
- Are Plozasiran clinical trials recruiting in 2026?
- Yes — 2 Plozasiran trials are actively recruiting in 2026, with 24 U.S. sites across 17 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Plozasiran being studied for?
- Plozasiran is being studied for Severe Hypertriglyceridemia, Familial Chylomicronemia, Hypertriglyceridemia, Familial Chylomicronemia Syndrome, High Risk Severe Hypertriglyceridemia (SHTG). The trials are grouped by indication on this page.
- What phase is Plozasiran in?
- Plozasiran clinical trials span 7 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Plozasiran clinical trials?
- The lead sponsor across the most Plozasiran trials is Arrowhead Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Plozasiranas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: